FGEN
Price
$5.61
Change
+$0.36 (+6.86%)
Updated
Jul 3 closing price
Capitalization
22.67M
36 days until earnings call
OVID
Price
$0.34
Change
+$0.01 (+3.03%)
Updated
Jul 3 closing price
Capitalization
24.06M
42 days until earnings call
Interact to see
Advertisement

FGEN vs OVID

Header iconFGEN vs OVID Comparison
Open Charts FGEN vs OVIDBanner chart's image
FibroGen
Price$5.61
Change+$0.36 (+6.86%)
Volume$33.07K
Capitalization22.67M
Ovid Therapeutics
Price$0.34
Change+$0.01 (+3.03%)
Volume$283.19K
Capitalization24.06M
FGEN vs OVID Comparison Chart in %
Loading...
FGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FGEN vs. OVID commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FGEN is a Hold and OVID is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (FGEN: $5.61 vs. OVID: $0.34)
Brand notoriety: FGEN and OVID are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FGEN: 80% vs. OVID: 28%
Market capitalization -- FGEN: $22.67M vs. OVID: $24.06M
FGEN [@Biotechnology] is valued at $22.67M. OVID’s [@Biotechnology] market capitalization is $24.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FGEN’s FA Score shows that 0 FA rating(s) are green whileOVID’s FA Score has 1 green FA rating(s).

  • FGEN’s FA Score: 0 green, 5 red.
  • OVID’s FA Score: 1 green, 4 red.
According to our system of comparison, OVID is a better buy in the long-term than FGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FGEN’s TA Score shows that 4 TA indicator(s) are bullish while OVID’s TA Score has 5 bullish TA indicator(s).

  • FGEN’s TA Score: 4 bullish, 5 bearish.
  • OVID’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, OVID is a better buy in the short-term than FGEN.

Price Growth

FGEN (@Biotechnology) experienced а +5.85% price change this week, while OVID (@Biotechnology) price change was -1.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

FGEN is expected to report earnings on Aug 11, 2025.

OVID is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OVID($24.1M) has a higher market cap than FGEN($22.7M). FGEN YTD gains are higher at: -57.620 vs. OVID (-63.757). OVID has more cash in the bank: 43M vs. FGEN (1.73M). OVID has less debt than FGEN: OVID (14.4M) vs FGEN (73.4M).
FGENOVIDFGEN / OVID
Capitalization22.7M24.1M94%
EBITDAN/A-56.4M-
Gain YTD-57.620-63.75790%
P/E RatioN/AN/A-
RevenueN/A548K-
Total Cash1.73M43M4%
Total Debt73.4M14.4M510%
FUNDAMENTALS RATINGS
FGEN vs OVID: Fundamental Ratings
FGEN
OVID
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
9363
P/E GROWTH RATING
1..100
5694
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OVID's Valuation (28) in the Pharmaceuticals Major industry is somewhat better than the same rating for FGEN (93) in the Biotechnology industry. This means that OVID’s stock grew somewhat faster than FGEN’s over the last 12 months.

OVID's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as FGEN (100) in the Biotechnology industry. This means that OVID’s stock grew similarly to FGEN’s over the last 12 months.

OVID's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as FGEN (100) in the Biotechnology industry. This means that OVID’s stock grew similarly to FGEN’s over the last 12 months.

OVID's Price Growth Rating (63) in the Pharmaceuticals Major industry is in the same range as FGEN (93) in the Biotechnology industry. This means that OVID’s stock grew similarly to FGEN’s over the last 12 months.

FGEN's P/E Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for OVID (94) in the Pharmaceuticals Major industry. This means that FGEN’s stock grew somewhat faster than OVID’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FGENOVID
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
88%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
79%
MACD
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
77%
Advances
ODDS (%)
N/A
Bullish Trend 4 days ago
73%
Declines
ODDS (%)
Bearish Trend 5 days ago
85%
Bearish Trend 24 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
FGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AVXL10.790.22
+2.08%
Anavex Life Sciences Corp
BLKB65.750.81
+1.25%
Blackbaud
KMI28.41-0.09
-0.32%
Kinder Morgan
FDMT4.24-0.07
-1.62%
4D Molecular Therapeutics
BCAB0.38-0.02
-5.43%
BioAtla

FGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, FGEN has been loosely correlated with AVTX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if FGEN jumps, then AVTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FGEN
1D Price
Change %
FGEN100%
+6.86%
AVTX - FGEN
57%
Loosely correlated
+0.40%
MGNX - FGEN
45%
Loosely correlated
+5.80%
OVID - FGEN
30%
Poorly correlated
+2.39%
DAWN - FGEN
30%
Poorly correlated
+1.04%
VTGN - FGEN
30%
Poorly correlated
-1.96%
More

OVID and

Correlation & Price change

A.I.dvisor indicates that over the last year, OVID has been closely correlated with JBIO. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if OVID jumps, then JBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
+2.39%
JBIO - OVID
79%
Closely correlated
+3.15%
BEAM - OVID
47%
Loosely correlated
+0.65%
TRDA - OVID
47%
Loosely correlated
N/A
DNLI - OVID
46%
Loosely correlated
-1.41%
CRNX - OVID
46%
Loosely correlated
+1.22%
More